TGA / PMDA / NMPA · Asia-Pacific
upadacitinib — TGA / PMDA / NMPA regulatory status
upadacitinib (RINVOQ) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: TGA approved · NMPA clinical trials.
Status snapshot
- Status
- TGA approved · NMPA clinical trials
- Brand
- RINVOQ
- Originator
- AbbVie
- Mechanism
- Tyrosine-protein kinase TYK2 inhibitor
- Structured fields
- 8
Sponsor / originator context: AbbVie. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Tyrosine-protein kinase TYK2 inhibitor. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — TGA: approved; NMPA: clinical trials.
Linked evidence on this spoke: 0 published clinical programs and 3 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2025221754 | UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES | WO |
| 2024398790 | TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB | US |
| 2024390367 | METHODS OF TREATING VITILIGO WITH UPADACITINIB | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of upadacitinib?
upadacitinib currently shows TGA approved · NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get upadacitinib regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.